Cheng Jinjun, Zhu Haiqing, Choi John Kim
1 Department of Pathology, University of Tennessee Health Science Center, Memphis, Tennessee, USA.
2 Department of Pathology, St Jude Children's Research Hospital, Memphis, Tennessee, USA.
Pediatr Dev Pathol. 2017 Jun;20(3):191-196. doi: 10.1177/1093526616689185. Epub 2017 Feb 8.
CD30 is a member of the tumor necrosis factor receptor superfamily, member 8 (TNFRSF8), and its normal expression is restricted to activated T and B cells. In tumor cells, CD30 expression is most commonly associated with lymphoid malignancies (Hodgkin and non-Hodgkin lymphomas) and is a therapeutic target using anti-CD30 antibody. CD30 expression has been reported also in mostly adult non-lymphoid malignancies, raising the possibility of CD30-targeted therapy for additional tumors. In this study, we examined the incidence of CD30 expression in 251 hematopoietic and 334 non-hematopoietic cases of pediatric tumors. As expected, strong and membranous CD30 staining was seen in anaplastic large cell lymphoma, classical Hodgkin lymphoma, and embryonal carcinoma while variable staining was seen in diffuse large B cell lymphoma. In addition, positive CD30 staining was also seen in cases of neuroblastoma (33 of 56), neoplasm with chondroid differentiation (8 of 25), myeloid neoplasms (11 of 120), hemangioma (2 of 12), and mature teratoma (1 of 11). In neuroblastoma, the CD30 expression was generally restricted to cells with ganglion differentiation; staining of ganglion cells was also seen in the one positive case of mature teratoma. In neoplasm with chondroid differentiation, the positive cases were chondrosarcoma (3 of 5), chondroblastic osteosarcoma (2 of 10), and chondroblastoma (3 of 7). In acute myeloid leukemia, the CD30 positive cases were more common in AML with monocytic differentiation but did not correlate with any specific molecular change. We conclude that CD30 expression in pediatric tumors is more general than anticipated and future studies are warranted to understand the biologic and therapeutic significances.
CD30是肿瘤坏死因子受体超家族成员8（TNFRSF8）的一员，其正常表达仅限于活化的T细胞和B细胞。在肿瘤细胞中，CD30表达最常与淋巴系统恶性肿瘤（霍奇金淋巴瘤和非霍奇金淋巴瘤）相关，并且是使用抗CD30抗体的治疗靶点。据报道，CD30表达也存在于大多数成人非淋巴系统恶性肿瘤中，这增加了针对其他肿瘤进行CD30靶向治疗的可能性。在本研究中，我们检测了251例儿童造血系统肿瘤和334例非造血系统肿瘤中CD30表达的发生率。正如预期的那样，在间变性大细胞淋巴瘤、经典霍奇金淋巴瘤和胚胎癌中可见强的膜性CD30染色，而在弥漫性大B细胞淋巴瘤中可见不同程度的染色。此外，在神经母细胞瘤（56例中的33例）、具有软骨样分化的肿瘤（25例中的8例）、髓系肿瘤（120例中的11例）、血管瘤（12例中的2例）和成熟畸胎瘤（11例中的1例）中也可见CD30阳性染色。在神经母细胞瘤中，CD30表达通常仅限于具有神经节分化的细胞；在1例成熟畸胎瘤阳性病例中也可见神经节细胞染色。在具有软骨样分化的肿瘤中，阳性病例为软骨肉瘤（5例中的3例）、成软骨细胞性骨肉瘤（10例中的2例）和成软骨细胞瘤（7例中的3例）。在急性髓系白血病中，CD30阳性病例在具有单核细胞分化的急性髓系白血病中更为常见，但与任何特定的分子变化均无相关性。我们得出结论，儿童肿瘤中CD30表达比预期更为普遍，有必要进行进一步研究以了解其生物学和治疗意义。
